Table 5 Sensitivity analyses
From: Economic evaluation of increasing population rates of cardiac catheterization
Parameter | Incremental cost-effectiveness ratio ($ per QALY) | ||
|---|---|---|---|
| Â | ACS (Yusuf RR) | ACS (FRISC-II RR) | Non-ACS |
Base case | $23,559 | $31,438 | $32,107 |
ACS specific yield (2.6:1 for males, 3.4:1 for females) | $22,187 | $30,768 | Â |
Non-ACS specific yield (2.5:1 for males, 5:1 for females) | Â | Â | $29,593 |
Disease yield for males (cost per QALY for male subgroup) | Â | Â | Â |
   Decreased to 4:1 catheterizations per high risk case detected | $28,335 | $34,139 | $34,673 |
   Increased to 2:1 catheterizations per high risk case detected | $21,973 | $32,167 | $25,466 |
Disease yield for females (cost per QALY for female subgroup) | Â | Â | Â |
   Decreased to 7:1 catheterizations per high risk case detected | $22,485 | $27,626 | $51,189 |
   Increased to 3:1 catheterizations per high risk case detected | $17,410 | $24,944 | $32,390 |
Relative risk of death associated with medical management compared to revascularisation | Â | Â | Â |
   Increase by 25% (revascularization more beneficial) | $13,300 | $18,717 | $17,884 |
   Decrease by 25% (revascularization less beneficial) | Dominated | $196,414 | Dominated |
Use of Seattle Angina Questionnaire disease specific quality of life measure | $20,975 | $27,575 | $26,264 |
Procedural Costs | Â | Â | Â |
   Increase by 50% | $30,631 | $41,228 | $40,540 |
   Decrease by 25% | $16,486 | $21,648 | $23,674 |
Costs of care | Â | Â | Â |
   Increase by 50% | $21,193 | $27,577 | $31,294 |
   Decrease by 25% | $24,741 | $33,368 | $32,513 |
Discount rate | Â | Â | Â |
   No discounting | $12,324 | $15,388 | $12,672 |
   3% discount rate | $19,300 | $25,307 | $24,276 |
   6% discount rate | $25,617 | $34,389 | $35,971 |